Explore
Validate
Learn18252-1-AP
antibody from Proteintech Group
Targeting: AKR1B10
AKR1B11, AKR1B12, ALDRLn, ARL-1, ARL1, HIS, HSI
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [6]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 18252-1-AP - Provider product page
- Provider
- Proteintech Group
- Product name
- AKR1B10 antibody
- Antibody type
- Polyclonal
- Description
- AKR1B10 antibody (Cat. #18252-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: WB,ELISA.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Mild Hyperuricemia Attenuates Salt-Sensitive Hypertension and Kidney Damage.
Dual tissue mRNA and serum protein signatures improve risk stratification in hepatocellular carcinoma.
Aldo-keto Reductase 1B10 (AKR1B10) Suppresses Sensitivity of Ferroptosis in TNBC by Activating the AKT/GSK3β/Nrf2/GPX4 Axis.
Matrix stiffness regulates glucose-6-phosphate dehydrogenase expression to mediate sorafenib resistance in hepatocellular carcinoma through the ITGB1-PI3K/AKT pathway.
Berberine directly targets AKR1B10 protein to modulate lipid and glucose metabolism disorders in NAFLD.
Mechanistic Analysis of an Extracellular Signal-Regulated Kinase 2-Interacting Compound that Inhibits Mutant BRAF-Expressing Melanoma Cells by Inducing Oxidative Stress.
Dissanayake LV, Zietara A, Bohovyk R, Klemens CA, Kravtsova O, Levchenko V, Lowe M, Shapiro A, Pasmanik V, Palygin O, Daehn IS, El-Meanawy A, Rieg T, Staruschenko A
Hypertension (Dallas, Tex. : 1979) 2025 Nov;82(11):2015-2026
Hypertension (Dallas, Tex. : 1979) 2025 Nov;82(11):2015-2026
Dual tissue mRNA and serum protein signatures improve risk stratification in hepatocellular carcinoma.
Guo DF, Fan LW, Wen Q, Wang JK, Liang YH, Feng Q, Wang T, Zhang KH
NPJ precision oncology 2025 Nov 17;9(1):354
NPJ precision oncology 2025 Nov 17;9(1):354
Aldo-keto Reductase 1B10 (AKR1B10) Suppresses Sensitivity of Ferroptosis in TNBC by Activating the AKT/GSK3β/Nrf2/GPX4 Axis.
Wu S, Yang G, Wen X, Lin Y, Wang S, Wang J, Liu Q, Luo D
Frontiers in bioscience (Landmark edition) 2025 Jun 27;30(6):36615
Frontiers in bioscience (Landmark edition) 2025 Jun 27;30(6):36615
Matrix stiffness regulates glucose-6-phosphate dehydrogenase expression to mediate sorafenib resistance in hepatocellular carcinoma through the ITGB1-PI3K/AKT pathway.
Ren R, Zhang S, Peng Z, Ji X, Song H, Wang Q, Sun X, Wang H, Dong Y
Cell death & disease 2025 Jul 20;16(1):538
Cell death & disease 2025 Jul 20;16(1):538
Berberine directly targets AKR1B10 protein to modulate lipid and glucose metabolism disorders in NAFLD.
Yang S, Cao SJ, Li CY, Zhang Q, Zhang BL, Qiu F, Kang N
Journal of ethnopharmacology 2024 Oct 5;332:118354
Journal of ethnopharmacology 2024 Oct 5;332:118354
Mechanistic Analysis of an Extracellular Signal-Regulated Kinase 2-Interacting Compound that Inhibits Mutant BRAF-Expressing Melanoma Cells by Inducing Oxidative Stress.
Martinez R 3rd, Huang W, Samadani R, Mackowiak B, Centola G, Chen L, Conlon IL, Hom K, Kane MA, Fletcher S, Shapiro P
The Journal of pharmacology and experimental therapeutics 2021 Jan;376(1):84-97
The Journal of pharmacology and experimental therapeutics 2021 Jan;376(1):84-97
No comments: Submit comment
No validations: Submit validation data